Aster Dm Healthcare Limited

Valuation mismatch: PE 133.7 against ROE 9.7% leaves minimal buffer for disappointment. What earnings growth rate or multiple expansion must hold for the premium to be justified?

Profitability instability: net profit ranged from ₹153.58 Cr (Mar 2026) to -₹14.3 Cr (Jun 2026) despite stable ~20% operating margins. Identify what triggered the loss and whether it recurs.

Revenue volatility: standalone figures alternate between high (~₹1.2 Tr) and low (~₹0.7 Tr) quarters. Verify whether this reflects genuine seasonality, segment reporting dynamics, or operational inconsistency.

Institutional confidence deteriorating: FII holdings fell from 17.18% (Mar 2026) to 10.53% (Jun 2026) in one quarter. What prompted the outflow and is further selling likely?

Operating margins held steady at 19–21% across all quarters despite revenue swings, showing cost structure can absorb volume growth without compression.

Debt-to-equity of 0.15 provides financial capacity for debt-funded capex or M&A to drive scale.

Regular dividend payments across 2024–2026 signal sustainable cash generation; verify free-cash-flow conversion and whether growth capital will be available alongside shareholder payouts.

1-year return of 38.3% and stock near 52-week highs (₹869.7) suggest momentum; verify whether this reflects operational improvement or market sentiment.